BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) will hold a conference call with investors this morning, Tuesday September 10, at 8:00 a.m. (ET) to discuss its partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) which the companies announced today.
The audio presentation will be broadcast online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171545. Investors can also access the presentation through the "Webcast" tab on Inovio's home page at www.inovio.com. This is a listen-only event but will include a live Q&A with analysts. An archived version of the webcast will be available for 90 days beginning two hours after the call.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target breast and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Roche entered into an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies targeting prostate cancer and hepatitis B. Other partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is av
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved